对家尘过敏的成年人进行皮下过敏原免疫疗法:第三阶段随机对照试验
Claus Bachert1, Hans Hoogeveen2, Rimko Ten Have2
1ENT-Dep, University of Muenster, Muenster, Germany.
Allergy
|September 18, 2025
概括
针对家用灰尘的皮下过敏原免疫疗法 (SCIT) 是安全的,但整体上没有达到主要疗效终点. 然而,它被证明对中度至重度过敏症状的患者有效,这表明基线严重程度对于证明SCIT益处至关重要.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮下过敏原免疫疗法 (SCIT) 是一种成熟的过敏治疗方法.
- 监管机构要求进行关键的III期试验,以确认SCIT的疗效和安全性,以便继续获得市场许可.
- 这项研究旨在满足家庭灰尘虫 (HDM) 制备的这些要求.
研究的目的:
- 确认一种特定的皮下室内灰尘虫 (HDM) 制剂的安全性和有效性.
- 为了评估与当前维持剂量相比,优化的更高剂量.
- 根据成功的II期研究进行随机对照试验.
主要方法:
- 一个随机对照试验,涉及767名受试者接受SCIT产品 (50,000AUeq/mL) 或安慰剂治疗一年.
- 主要终点是鼻腔症状的综合症状和药物评分 (CSMS(n)).
- 受试者根据基线症状严重程度 (轻度与中度至重度) 分层.
主要成果:
- 整体研究未达到主要终点,仅显示改善趋势 (p=0.0767) 并未达到临床相关差异的最小值.
- 对患有中度至重度HDM过敏症状 (n=228) 的患者进行的特设后期分析显示,主要终点 (p=0.0031) 的显著和临床意义上的减少显著.
- 在中度至重度症状的小组中,没有发现安全性问题增加.
结论:
- 经过测试的SCIT产品在50,000AUeq/mL下是安全的,并且耐受性很好.
- 整体缺乏疗效可能归因于将高比例的轻度症状患者纳入治疗.
- 在中度至重度的HDM诱导过敏性鼻炎患者中,SCIT证明了疗效,这凸显了基线症状严重程度对未来试验的重要性.
相关概念视频
02:06Allergic Reactions
26.4K
Overview
26.4K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:30Allergic Reactions: Anaphylaxis
280
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
280
01:28Asthma I: Introduction
112
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
112
01:13Asthma III: Clinical Manifestations
49
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
49